Abstract
Paroxetine has been introduced in 1993 used for the treatment of depression, panic, anxiety, obsessive compulsive disorders (OCD) and other related disorders. Paroxetine has the strongest inhibition of serotonin uptake but is less specific than other SSRIs. The FDA approval in adult population are Major depressive disorder, obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. The systemic review with literatures about the clinical uses, pharmacokoinetic properties has been discussed. Its safety especially in paediatric population, various adverse effects, ACOG guidelines, FDA black box warnings are reviewed. Discontinuation reaction of Paroxetine and various adverse reactions are largely unknown to general practioners. In India this drug has been restricted to prescriptions of specialists only which limit the beneficial effects of this molecule to larger population. More awareness is required to extend benefits to general population as it is getting newer approval including use to reduce post menopausal hot flashes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Psychology and Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
